Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T induced resistance in ALL

Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

Key clinical point: Unintentional transduction of a single leukemic B cell induced resistance to CTL019 (tisagenlecleucel) therapy.

Major finding: A patient with B-cell acute lymphoblastic leukemia (B-ALL) had frank relapse 9 months after a CTL019 infusion, with more than 90% bone marrow infiltration of chimeric antigen receptor–transduced B-cell leukemia cells.

Study details: A case study of a 20-year-old male with B-ALL undergoing CTL019 therapy.

Disclosures: Study funding was provided by Bristol-Myers Squibb, Novartis, the National Institutes of Health, and others. Dr. Ruella and several of his colleagues work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research and are inventors of intellectual property licensed by the University of Pennsylvania to Novartis.

Read the article here.

Citation:

Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9.

This Week's Must Reads

Program reduces ER admissions and inpatient costs, Mendenhall M et al. Quality Care Symposium, Abstract 30

Pain severity decreased over time with app, Kamdar MM et al. PallOnc 2018, Abstract 76

National health care spending growth slowed to 3.9% in 2017 , Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085

Federal proposal aims to move doctors back to face-to-face interventions, Office of the National Coordinator for Health IT

Must Reads in Immuno-oncology

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514

Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9